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Background: Erythropoiesis-stimulating agents, for example epoetin beta pegol which is a continuous
erythropoietin receptor activator (CERA), and darbepoetin alfa (DPO), are recently introduced into clinical practice
for the treatment of anemia in hemodialysis patients. Here, we compared the effects of CERA and DPO on
erythropoiesis and iron kinetics in hemodialysis patients.
Methods: In this open label, single arm trial, after 40 μg/week of DPO administration, 75 μg/2 weeks of CERA was
administered during 14 days in 7 hemodialysis patients without clinically overt inflammation or infection.
Serum parameters of erythropoietic activity (hemoglobin) and iron kinetics (hepcidin-25 [hepcidin], ferritin,
high-sensitivity C-reactive protein and transferrin saturation [TSAT]) were evaluated during the study periods.
Results: DPO significantly increased the hemoglobin levels above the baseline, as compared to the insignificant
increase by CERA. Suppression of serum ferritin was more significant during CERA than DPO (P = 0.018), while TSAT
or serum hepcidin did not differ significantly between CERA and DPO (TSAT, P = 0.866; hepcidin, P = 0.063). Our
results suggested that, under conditions indicating a significantly weaker effect of CERA than DPO on
erythroblastosis, the greater suppression of serum ferritin by CERA might indicate its potent effect on iron
utilization.
Conclusions: The effect of CERA administered once every 2 weeks exhibited no less potent effect in terms of iron
utilization than that of DPO administered every week.
Keywords: Darbepoetin alfa, Epoetin beta pegol, Ferritin, Hepcidin, Transferrin saturation, Hemoglobin, Iron
utilization, HemodialysisBackground
Erythropoiesis-stimulating agents (ESAs), such as re-
combinant human erythropoietin (rHuEPO), darbepoe-
tin alfa (DPO), and epoetin beta pegol (continuous
erythropoietin receptor activator; CERA) are widely used
in current clinical practice for the treatment of anemia
in hemodialysis patients. Because of the different half-
lives of these ESAs in circulation after intravenous
administrations (rHuEPO, 8.5 h; DPO, 25.3 h; CERA,
approx. 130 h), an appropriate administration regimen
for each agent should be determined [1]. For example,* Correspondence: junpeach43358@yahoo.co.jp
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administered thrice and once a week, respectively [2],
the longest-acting CERA is conventionally administered
once every 2 or 4 weeks [3]. To enable more stabilized
hemoglobin levels after switching the erythropoiesis-
stimulating agent (ESA) from weekly administration of
DPO to CERA, it is strongly recommended to adminis-
ter CERA every 2 weeks [4]. We have recently reported
that longer-acting DPO might increase the utilization of
iron from the body store more for bone marrow erythro-
poiesis in terms of its greater suppression of serum
hepcidin while maintaining TSAT >20 % than shorter-
acting rHuEPO [5]. According to the 2008 Japanese
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tained >20 %, iron supplementation should be stopped
when the serum ferritin level increases ≥100 ng/mL [5].
Due to the recent development of a precise assay for
hepcidin [7], the serum level of hepcidin has been recog-
nized as a relevant indicator for iron utilization for
erythropoiesis [8]. Metabolism of hepcidin is tightly reg-
ulated by erythroferrone produced by erythroblasts,
which increases as the erythropoietic activity of the bone
marrow becomes elevated [9].
In the present study, we compared the effects of DPO
administered once per week with those of CERA once
every 2 weeks on iron kinetics and erythropoiesis in
Japanese hemodialysis patients in an open label, single
arm trial design during the total study period of 4 weeks.
Methods
Patients
All patients provided informed consent to participate in the
study after being individually explained the study protocol
and associated risks. The present study protocol was ap-
proved by the Ethical Committee of Social Care Corpor-
ation at Keigakukai South Osaka Hospital (2014-4).
The inclusion criteria were a clinically stable condition
particularly in terms of hemoglobin (Hb) levels and the
dose of rHuEPO, as well as iron metabolism for
3 months before the start of the present study. All en-
rolled patients had received rHuEPO (3000 IU × 3/week)
for more than 3 months prior to enrolment, had stable
hemoglobin levels (10.0–12.0 g/dL; variation <0.5 g/dL
in the three months prior to enrolment), and transferrin
saturation (TSAT) >20 % and serum ferritin >50 ng/mL.
Patients who are smokers and have other conditions
likely to affect Hb levels, such as acute inflammation, in-
fection, or cardiovascular disease, were excluded from
the study. Acute inflammation and infection were de-
fined by the presence of symptoms together with a
serum C-reactive protein (CRP) level above the upper
limit of normal of 0.4 mg/dL. The presence of cardiovas-
cular disease was evaluated based on clinical information
regarding coronary, cerebral and peripheral artery dis-
eases, and aortic aneurysm. Coronary artery disease was
diagnosed when a subject had one or more of the fol-
lowing criteria: (1) past history of percutaneous coronary
intervention or coronary artery bypass grafting, (2) pres-
ence of significant stenosis by coronary angiography, (3)
presence of ST-T abnormalities on electrocardiogram as-
sociated with typical symptoms attributable to angina
pectoris, and (4) use of one or more medication for cor-
onary ischemia, as we have described previously [10].
None of the patients were iron-deficient on the basis of
the absence of anemia and normal erythropoietin re-
sponsiveness index. Patients with evidence for marked
inflammation or infection were excluded.Study design
Seven outpatients (three male and four female), who had
received maintenance hemodialysis for at least 6 months at
Minami-Osaka Dialysis Clinic (Osaka, Japan), were enrolled
in the study. The design of this open label, single arm trial
is as follows. At the beginning of the study, rHuEPO
(3000 IU × 3/week) was first continuously administered for
3 months and then withdrawn for a washout period of
7 days. Weekly DPO administration was then initiated for
14 days (administered weekly on days 0 and 7 at a dose of
40 μg/week), which was immediately followed by rHuEPO
administration for 4 weeks (3000 IU × 3/week). After
rHuEPO administration was again stopped for a washout
period of 1 week, CERA was administered once on day 0 at
a dose of 75 μg without any administration of ESA for the
subsequent 14 days.
During the two 14-day treatment periods with DPO and
CERA, biochemical parameters for bone marrow erythro-
poiesis and iron metabolism were monitored. No drugs
that might affect erythropoietic activity or iron utilization
were administrated during the study period. Hemoglobin
level and serum parameters of iron metabolism (TSAT,
serum ferritin and serum hepcidin) were measured imme-
diately before ESA administration and also before the start
of the hemodialysis session on days 0, 2, 4, 7, 9, 11, and 14
during the treatment periods with DPO and CERA. Serum
high-sensitivity C-reactive protein level (hs-CRP) was
measured on days 0, 7, and 14. Utilization of iron was
evaluated based on the area under the serum concentra-
tion–time curves of TSAT, serum ferritin, and serum hep-
cidin during the administration periods.Blood samples and determination of serum markers
Blood samples were collected, kept on ice for 1 h, centri-
fuged at 1000 × g for 10 min, aliquoted, and then stored at
−80 °C until assay. Serum hepcidin level was quantified by
liquid chromatography tandem mass spectrometry (LC-
MS/MS) [7]. Serum ferritin was measured with a solid
phase two-site chemiluminescence immunometric assay
(Abbott Japan, Tokyo, Japan). Serum iron and total iron-
binding capacity (TIBC) were determined using the batho-
phenanthroline method (Wako Pure Chemical Industries
Ltd, Osaka, Japan). TSAT was calculated as serum iron
(μg/dL)/TIBC (μg/dL) × 100(%). Serum hs-CRP level was
determined with a latex turbidimetric immunoassay using
an N-Assay LA CRP-S D-Type kit (Nittobo Medical,
Tokyo, Japan).
Serum ferritin, hepcidin, hemoglobin, hs-CRP, and TSAT
are parameters of renal anemia and therefore representa-
tives of iron kinetics. Hence, we assessed the changes in
their levels during the study period, and intergroup com-
parisons were performed between the two administration
periods. The degree of suppression in serum ferritin, TSAT,
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estimated.Statistical analyses
Values are expressed as the mean ± standard deviation
(SD). Changes in serum biomarkers in addition to the
relative changes of serum ferritin, TSAT, and hepcidin
were compared during the DPO and CERA administra-
tion periods using the Wilcoxon signed-rank test due to
the small number of patients in the present study.
The areas under the serum concentration–time curves
(AUC) of ferritin, TSAT, and hepcidin were estimated by
the trapezoidal rule and analyzed with the Wilcoxon
signed-rank test.
The AUC was calculated based on the area between
each curve and value at day 0 during the observation
period from the data illustrated in Fig. 1. Since the AUC
was obtained in each patient with the conversion of
AUC expressed in value x days, SDs were obtained for
TSAT, ferritin, and hepcidin.a b
d e
Fig. 1 Effects of DPO and CERA on hemoglobin (a), TSAT (b), serum ferritin (c
(e) during the 14 days of treatment period. Data are expressed as mean ± SD,A P value <0.05 was considered to be significant.
StatView version 5.0.1 software (SAS Institute Inc,
Cary, NC) was used for the statistical analyses.
Results
Patient characteristics
The baseline characteristics of the patients enrolled in
the study are shown in Table 1. No significant difference
was found in hemoglobin, serum iron, serum ferritin,
TSAT, hepcidin, hs-CRP, albumin, body weight, or
Δbody weight between DPO and CERA administration
(Table 1).
Changes in serum parameters for erythropoiesis and iron
metabolism during DPO or CERA administration
As shown in Fig. 1a, DPO administration significantly
increased the hemoglobin level from 10.5 ± 0.34 to 10.9
± 0.34 g/dL (P = 0.034), while CERA administration did
not significantly affect the hemoglobin level during the
treatment period of 14 days. Furthermore, hemoglobin
level was significantly higher on day 11 during DPOc
), serum hepcidin (d), and high-sensitivity C-reactive protein (hs-CRP)
†p < 0.05 vs. DPO baseline, §p < 0.05 vs. CERA baseline, *p < 0.05 vs. DPO
Table 1 Baseline characteristics of patient subjects at the start of DPO CERA treatment
At the time of DPO treatment At the time of CERA treatment P value
Hemoglobin (g/dL) 10.5 ± 0.34 10.4 ± 0.75 0.799
Serum iron (μg/dL) 82.4 ± 26.34 89.3 ± 26.62 0.447
Serum ferritin (ng/mL) 160.69 ± 66.84 163.67 ± 67.40 0.612
TSAT (%) 45.3 ± 17.82 39.8 ± 9.44 0.311
Hepcidin (ng/mL) 98.9 ± 35.42 79.3 ± 27.95 0.176
hs-CRP (mg/dL) 0.19 ± 6.81 0.07 ± 5.01 0.112
Albumin (g/dL) 3.5 ± 0.29 3.7 ± 0.22 0.106
Body weight (kg) 57.9 ± 5.2 58.2 ± 5.0 0.229
ΔBody weight (kg)a 0.07 ± 0.45 0.30 ± 0.56 0.501
Sex (M/F, n) is 3/4
The age (years) is 72.3 ± 7.63
The hemodialysis duration (months) is 66.9 ± 60.9
aIs the change of body weight during the 14 days of DPO and CERA treatment
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vs. 10.3 ± 0.89 g/dL, P = 0.018). However, hemoglobin
levels did not significantly differ between DPO and
CERA administrations on day 0 and day 14.
While DPO administration did not noticeably change
TSAT during the treatment period of 14 days, CERA ad-
ministration significantly suppressed TSAT in a progres-
sive time-dependent manner from day 0 up to day 7
(day 0, 39.8 ± 9.44 % vs. day 4, 27.8 ± 5.84 %, P = 0.018;
vs. day 7, 19.8 ± 5.48 %, P = 0.018) and remained sup-
pressed on day 9 (28.1 ± 7.33 %, P = 0.028). TSAT was
significantly lower on day 7 during CERA administration
than DPO administration (Fig. 1b).
While DPO administration suppressed serum ferritin
initially on day 14, CERA administration significantly
suppressed serum ferritin from the baseline value of
163.7 ± 67.4 to 136.0 ± 54.2 ng/mL on day 7 (P = 0.018),
122.1 ± 53.0 ng/mL on day 9 (P = 0.018) and 122.7 ±
51.1 ng/mL on day 11 (P = 0.018). Serum ferritin level
significantly decreased during CERA administration
than DPO administration on day 7 (136.0 ± 54.2 vs.
154.5 ± 60.0 ng/mL, P = 0.043) and day 9 (122.1 ± 53.0
vs. 163.5 ± 59.9 ng/mL, P = 0.018) (Fig. 1c).
Serum hepcidin level was significantly suppressed by
day 2 after the start of either DPO or CERA administra-
tion. However, serum hepcidin began to increase towards
the normal baseline by day 11 during CERA treatment,
whereas DPO maintained the suppression of serum hepci-
din during the treatment period of 14 days, with serum
hepcidin levels being significantly lower on days 11 and 14
during DPO administration than CERA administration.
Serum hepcidin level was significantly suppressed during
CERA administration than DPO administration on day 7
(15.6 ± 11.7 vs. 27.8 ± 11.3 ng/mL, P = 0.028), whereas
serum hepcidin level significantly was suppressed during
DPO administration than CERA administration on day 11
(18.9 ± 19.8 vs. 39.7 ± 15.6 ng/mL, P = 0.028) and day 14(34.0 ± 19.7 vs. 66.7 ± 16.0 ng/mL, P = 0.028) (Fig. 1d). In
contrast, serum hs-CRP level did not change significantly
during DPO or CERA administration (Fig. 1e).
Suppression of parameters of iron utilization during DPO
and CERA administration
Figure 2 shows the effects of DPO and CERA suppression
on TSAT (a), ferritin (b), and hepcidin (c), which were esti-
mated from the area under the respective curve during the
14 days of treatment. As shown in Fig. 2b, the suppression
of serum ferritin was significantly greater during CERA
administration than DPO administration (CERA vs. DPO;
220.6 ± 284.56 vs. −36.0 ± 295.01 ng/mL*day; P = 0.018). As
shown in Fig. 2a, c, the suppressions of TSAT (CERA vs.
DPO; P = 0.866) and serum hepcidin (CERA vs. DPO; P =
0.063) did not differ significantly between CERA and DPO
administration.
Discussion
We recently reported that the suppressive effect of
serum hepcidin and ferritin was significantly stronger by
DPO than short-acting rHuEPO [6]. Therefore, to con-
firm the superiority of DPO on iron utilization, we made
the study design to treat the enrolled patients firstly with
DPO and then secondly with CERA in Japanese
hemodialysis patients.
In the present study, all enrolled patients who require
3000 IU of rHuEPO three times a week to keep the tar-
get Hb level seem to have a relatively ESA-resistant
property. However, to elucidate whether DPO or CERA
might be better in terms of iron utilization, it seemed
more appropriate to examine their effect in the patients
with a relatively ESA-resistant property.
Although CERA administration (single dose of 75 μg
on day 0 during 14 days of treatment) was no less potent
than DPO administration (single dose of 40 μg on each
of day 0 and day 7 during 14 days of treatment) in the
a b c
Fig. 2 Effects of each ESA in the suppression of TSAT (a), serum ferritin (b), and serum hepcidin (c) are estimated from the area under the
respective curve during the 14 days of treatment period. Data are expressed as mean ± SD, *p < 0.05 vs. DPO
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these parameters began to increase by 14 days after sin-
gle administration of 75 μg CERA. However, based on
the AUC during 14 days of CERA and DPO treatment,
the effects of CERA to suppress serum hepcidin and
TSAT did not differ significantly from those of DPO, al-
though CERA was more potent than DPO in the sup-
pression of serum ferritin.
Because of the time-course of serum hepcidin, it is con-
ceivable that the erythropoietic activity of CERA might be
diminished after 9 days of CERA administration, while the
erythropoietic activity of DPO remained persistent
throughout 7 days of DPO administration. The greater po-
tency of CERA in the suppression of serum hepcidin on
day 7 might lead to the significant suppression of serum
ferritin. Conversely, an increase of serum hepcidin in the
CERA-treated group might be associated with significant
increase of serum ferritin (Fig. 1). However, during the
14 days of treatment period, it was suggested that the effect
of CERA might have greater potency than DPO to suppress
serum ferritin, in contrast with the insignificant difference
in the potencies to suppress serum hepcidin between two
ESAs.
It has been previously reported that serum ferritin
might be reduced as the ESA efficiently improves anemia
by suppressing serum hepcidin to increase iron move-
ment from the body iron store into circulation [11]. In
the present study, DPO administration significantly in-
creased the hemoglobin level, while CERA administra-
tion did not significantly affect the hemoglobin level
during the treatment period of 14 days. However, as
shown in Fig. 2, the suppression of serum ferritin was
significantly greater during CERA administration thanDPO administration, while serum hepcidin did not differ
significantly between CERA and DPO administration.
Therefore, our result suggested that CERA might be a
more superior ESA in iron utilization.
In hemodialysis patients, iron supplementation, which
might compensate for the iron loss due to blood loss
into the dialysis circuit during each hemodialysis ses-
sion, is essential in treating anemia and to increase the
EPO responsiveness to ESA dosage [12, 13]. However,
iron overload may increase oxidative stress [14] and
leave patients at risk for infection [15], arteriosclerosis
[16], and viral hepatitis [17]. Furthermore, we have re-
cently reported that administration of intravenous iron
in hemodialysis patients increases the all-cause mortal-
ity in a dose-dependent manner, which is independent
of serum TSAT and ferritin levels, suggesting that iron
alone might directly exert a harmful effect in
hemodialysis patients [18].
Serum ferritin level, which represents total body iron
stores, might provide a relevant measure for the risk of
infection and cardiovascular events, as well as mortality
in hemodialysis patients [19]. In patients undergoing
hemodialysis, it has been shown that a higher serum fer-
ritin level is associated with a high incidence of
bacteremia [20] and a reduction in the phagocytic ability
of leukocytes [21]. Previous studies have additionally
shown that a high serum ferritin level is associated with
hospitalization, morbidity, and an all-cause mortality in
hemodialysis patients [22, 23].
In Japan, since the harmful effect of iron has long been
advocated to iron-usage restriction, we reported that
intravenous administration of iron is significantly lower
in Japan than other countries [24].
Sawa et al. Renal Replacement Therapy  (2016) 2:26 Page 6 of 7As the harmful effect of iron overload becomes more
widely appreciated, guidelines for renal anemia in chronic
kidney disease released by the Japanese Society for Dialysis
Therapy [5] recommended that serum ferritin levels in
hemodialysis patients should be kept lower [25].
Serum hepcidin regulates the cellular iron exporter
protein ferroportin and is therefore recognized as the
rate-limiting factor in the mobilization of iron across cell
membranes and into circulation [26]. There is a positive
correlation between serum levels of ferritin and hepci-
din, indicating that high serum ferritin levels reduce the
overall supply of iron into the circulation available for
erythropoiesis [11]. Indeed, a study examining the cor-
relation between serum hepcidin level and prognosis in
patients undergoing hemodialysis has shown that pa-
tients with high serum hepcidin frequently experience
cardiovascular events [27], indicating that serum hepci-
din is likely a useful index for cardiovascular risk inde-
pendent of serum ferritin.
It is recently reported that erythroferrone, produced
by erythroblast in response to EPO [8], suppressed hep-
cidin production during hematopoiesis to increase the
utilization of iron for bone marrow erythropoiesis.
Therefore, it is theoretically assumed that the potency of
ESAs to increase erythroblastosis should be negatively
associated with their effect to suppress serum hepcidin.
In this study, there were no significant differences of
erythropoietic activity and the suppression of hepcidin
between CERA and DPO administrations. It is possible
that the greater suppressive effect of CERA on serum
ferritin might be a more potent effect of CERA in the
utilization of iron for erythroblastosis.
There are several limitations in the present study.
First, this study is an open label, single arm trial. Second,
CERA was injected only once, so it might not represent
a stable response to this agent. Furthermore, the number
of patients was rather small, and the observation period
was short to elucidate the true phenomenon.
Therefore, although the suppressive effect of CERA on
serum ferritin seemed greater than that of DPO from
the present study, it is yet to be concluded whether the
effect of CERA might be more potent than that of DPO
from the standpoint of iron utilization.
Conclusions
The effect of CERA administered once every 2 weeks
exhibited no less potent effect in terms of iron utilization
than that of DPO administered every week.
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